Telix Pharmaceuticals completes proof-of-concept study for TLX592, an investigational antibody-based targeted alpha therapy for prostate cancer.

Telix Pharmaceuticals completes proof-of-concept study for TLX592, an investigational antibody-based targeted alpha therapy for prostate cancer. Study shows rapid blood circulation elimination and liver clearance, desirable for alpha-emitting agents. Successful dose escalation sets baseline for future studies using actinium-225. Data supports advancement to a therapeutic Phase I/II study in H2 2024.